129 related articles for article (PubMed ID: 37222949)
1. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry.
Cobo Marcos M; de la Espriella R; Gayán Ordás J; Zegrí I; Pomares A; Llácer P; Fort A; Rodríguez Chavarri A; Méndez A; Blázquez Z; Caravaca Pérez P; Rubio Gracia J; Recio-Mayoral A; García Pinilla JM; Soler MJ; Garrido González R; Górriz JL; González Rico M; Castro A; Núñez J
Curr Heart Fail Rep; 2023 Jun; 20(3):157-167. PubMed ID: 37222949
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry.
Cobo Marcos M; de la Espriella R; Gayán Ordás J; Llàcer P; Pomares A; Fort A; Ponz de Antonio I; Méndez A; Blázquez-Bermejo Z; Caravaca Pérez P; Rubio Gracia J; Recio-Mayoral A; Zegrí I; García Pinilla JM; Montero Hernández E; Castro A; Soler MJ; Górriz JL; Bascompte Claret R; Fluvià-Brugués P; Manzano L; Núñez J
Rev Esp Cardiol (Engl Ed); 2024 Jan; 77(1):50-59. PubMed ID: 37217135
[TBL] [Abstract][Full Text] [Related]
3. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.
Nayor M; Larson MG; Wang N; Santhanakrishnan R; Lee DS; Tsao CW; Cheng S; Benjamin EJ; Vasan RS; Levy D; Fox CS; Ho JE
Eur J Heart Fail; 2017 May; 19(5):615-623. PubMed ID: 28217978
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study.
Halimi JM; de Fréminville JB; Gatault P; Bisson A; Gueguen J; Goin N; Sautenet B; Maisons V; Herbert J; Angoulvant D; Fauchier L
Nephrol Dial Transplant; 2022 Nov; 37(12):2386-2397. PubMed ID: 35438794
[TBL] [Abstract][Full Text] [Related]
5. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Sartipy U; Dahlström U; Fu M; Lund LH
JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
[TBL] [Abstract][Full Text] [Related]
6. Incidence and impact of cardiorenal anaemia syndrome on all-cause mortality in acute heart failure patients stratified by left ventricular ejection fraction in the Middle East.
Al-Jarallah M; Rajan R; Al-Zakwani I; Dashti R; Bulbanat B; Sulaiman K; Alsheikh-Ali AA; Panduranga P; AlHabib KF; Al Suwaidi J; Al-Mahmeed W; AlFaleh H; Elasfar A; Al-Motarreb A; Ridha M; Bazargani N; Asaad N; Amin H
ESC Heart Fail; 2019 Feb; 6(1):103-110. PubMed ID: 30315634
[TBL] [Abstract][Full Text] [Related]
7. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
8. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
[TBL] [Abstract][Full Text] [Related]
9. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
11. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
Stolfo D; Uijl A; Vedin O; Strömberg A; Faxén UL; Rosano GMC; Sinagra G; Dahlström U; Savarese G
JACC Heart Fail; 2019 Jun; 7(6):505-515. PubMed ID: 31146874
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease.
Bansal N; Zelnick LR; Scherzer R; Estrella M; Shlipak MG
Circ Heart Fail; 2024 May; 17(5):e011173. PubMed ID: 38742428
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal syndrome type 4: A study of cardiovascular diseases in chronic kidney disease.
H S; B S A; Moger V; Swamy M
Indian Heart J; 2017; 69(1):11-16. PubMed ID: 28228293
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
Zafrir B; Lund LH; Laroche C; Ruschitzka F; Crespo-Leiro MG; Coats AJS; Anker SD; Filippatos G; Seferovic PM; Maggioni AP; De Mora Martin M; Polonski L; Silva-Cardoso J; Amir O;
Eur Heart J; 2018 Dec; 39(48):4277-4284. PubMed ID: 30325423
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and 30-day readmissions for heart failure with reduced ejection fraction with cardiorenal syndrome: A National Cohort Study.
Shanah L; Mir T; Uddin MM; Hussain T; Parajuli T; Bhat Z
Int J Cardiol; 2023 Jan; 370():244-249. PubMed ID: 36328112
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
17. The CRAS-EAHFE study: Characteristics and prognosis of acute heart failure episodes with cardiorenal-anaemia syndrome at the emergency department.
Llauger L; Jacob J; Herrero-Puente P; Aguirre A; Suñén-Cuquerella G; Corominas-Lasalle G; Llorens P; Martín-Sánchez FJ; Gil V; Roset A; Ruibal JC; Pérez-Durá MJ; Juan-Gómez MÁ; Garrido JM; Richard F; Lucas-Imbernon FJ; Alonso H; Tost J; Gil C; Miró Ò;
Eur Heart J Acute Cardiovasc Care; 2020 Aug; 9(5):406-418. PubMed ID: 32403935
[TBL] [Abstract][Full Text] [Related]
18. Stroke and Systemic Embolism and Other Adverse Outcomes of Heart Failure With Preserved and Reduced Ejection Fraction in Patients With Atrial Fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]).
Chung S; Kim TH; Uhm JS; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Kim CS; Lee YS; Shim J; Joung B
Am J Cardiol; 2020 Jan; 125(1):68-75. PubMed ID: 31699363
[TBL] [Abstract][Full Text] [Related]
19. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
Kroshian G; Joseph J; Kinlay S; Peralta AO; Hoffmeister PS; Singh JP; Yuyun MF
J Cardiovasc Electrophysiol; 2024 Apr; 35(4):715-726. PubMed ID: 38348517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
